Molecular gymnastics: Mechanisms of HIV-1 resistance to CCR5 antagonists and impact on virus phenotypes

Current Topics in Medicinal Chemistry

Volumn 16, Issue 10, 2016, Pages 1091-1106

  Roche, Michael ^a,b   Borm, Katharina ^b,c   Flynn, Jacqueline K ^b,d   Lewin, Sharon R ^a,d   Churchill, Melissa J ^b   Gorry, Paul R ^a,b,d,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e RMIT UNIVERSITY   (Australia)

Author keywords

CCR5; Envelope; HIV 1; Maraviroc; Resistance; Tropism

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; ANCRIVIROC; APLAVIROC; CD4 ANTIGEN; CENICRIVIROC; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 1; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEUTRALIZING ANTIBODY; POTASSIUM CHANNEL HERG; RANTES; VICRIVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR5;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CROSS RESISTANCE; DISEASE COURSE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VIRAL TROPISM; VIRUS ENTRY; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; METABOLISM; PHENOTYPE; PHYSICAL EDUCATION; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CCR5 RECEPTOR ANTAGONISTS; DRUG RESISTANCE, VIRAL; GYMNASTICS; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; RECEPTORS, CXCR5;

EID: 84962564581     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150901114724     Document Type: Article

References (184)

1. Gorry, P.R.; Ancuta, P. Coreceptors and HIV-1 pathogenesis. Curr. HIV/AIDS Rep., 2011, 8(1), 45-53.
2. Wilen, C.B.; Tilton, J.C.; Doms, R.W. HIV: cell binding and entry. Cold Spring Harb. Perspect Med., 2012, 2(8).
3. Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 1984, 312(5996), 763-7.
4. Maddon, P.J.; Dalgleish, A.G.; McDougal, J.S.; Clapham, P.R.; Weiss, R.A.; Axel, R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell, 1986, 47(3), 333-48.
5. McDougal, J.S.; Kennedy, M.S.; Sligh, J.M.; Cort, S.P.; Mawle, A.; Nicholson, J.K. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science, 1986, 231(4736), 382-5.
6. Alkhatib, G.; Combadiere, C.; Broder, C.C.; Feng, Y.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science, 1996, 272(5270), 1955-8.
7. Dragic, T.; Litwin, V.; Allaway, G.P.; Martin, S.R.; Huang, Y.; Nagashima, K.A.; Cayanan, C.; Maddon, P.J.; Koup, R.A.; Moore, J.P.; Paxton, W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 1996, 381(6584), 667-73.
8. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; Davis, C.B.; Peiper, S.C.; Schall, T.J.; Littman, D.R.; Landau, N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996, 381(6584), 661-6.
9. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P.D.; Wu, L.; Mackay, C.R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 1996, 85(7), 1135-48.
10. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272(5263), 872-7.
11. Berger, E.A.; Doms, R.W.; Fenyo, E.M.; Korber, B.T.; Littman D.R.; Moore J.P.; Sattentau Q.J.; Schuitemaker H.; Sodroski, J.; Weiss, R.A. A new classification for HIV-1. Nature, 1998, 391(6664), 240.
12. Gorry, P.R.; Francella, N.; Lewin, S.R.; Collman, R.G. HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies. J. Leukoc Biol., 2014, 95(1), 71-81.
13. Fenyo, E.M.; Fiore, J.; Karlsson, A.; Albert, J.; Scarlatti, G. Biological phenotypes of HIV-1 in pathogenesis and transmission. Antibiot. Chemother. (1971), 1994, 46, 18-24.
14. van’t Wout, A.B.; Kootstra, N.A.; Mulder-Kampinga, G.A.; Albrecht-van, L. N.; Scherpbier, H.J.; Veenstra, J.; Boer, K.; Coutinho, R.A.; Miedema, F.; Schuitemaker, H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J. Clin. Invest., 1994, 94(5), 2060-7.
15. Zhu, T.; Mo, H.; Wang, N.; Nam, D.S.; Cao, Y.; Koup, R.A.; Ho, D.D. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science, 1993, 261(5125), 1179-81.
16. Tersmette, M.; Gruters, R.A.; de Wolf, F.; de Goede, R.E.; Lange, J.M.; Schellekens, P.T.; Goudsmit, J.; Huisman, H.G.; Miedema, F. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol., 1989, 63(5), 2118-25.
17. Schuitemaker, H.; Koot, M.; Kootstra, N.A.; Dercksen, M.W.; de Goede, R.E.; van Steenwijk, R.P.; Lange, J.M.; Schattenkerk, J.K.; Miedema, F.; Tersmette, M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol., 1992, 66(3), 1354-60.
18. Koot, M.; Keet, I.P.; Vos, A.H.; de Goede, R.E.; Roos, M.T.; Coutinho, R.A.; Miedema, F.; Schellekens, P.T.; Tersmette, M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med., 1993, 118(9), 681-8.
19. Connor, R.I.; Sheridan, K.E.; Ceradini, D.; Choe, S.; Landau, N.R. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J. Exp. Med., 1997, 185(4), 621-8.
20. Bleul, C.C.; Wu, L.; Hoxie, J.A.; Springer, T.A.; Mackay, C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A., 1997, 94(5), 1925-30.
21. Lee, B.; Sharron, M.; Montaner, L.J.; Weissman, D.; Doms, R.W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocytederived macrophages. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(9), 5215-20.
22. Lee, B.; Sharron, M.; Blanpain, C.; Doranz, B.J.; Vakili, J.; Setoh, P.; Berg, E.; Liu, G.; Guy, H.R.; Durell, S.R.; Parmentier, M.; Chang, C.N.; Price, K.; Tsang, M.; Doms, R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem., 1999, 274(14), 9617-26.
23. Wu, L.; LaRosa, G.; Kassam, N.; Gordon, C.J.; Heath, H.; Ruffing, N.; Chen, H.; Humblias, J.; Samson, M.; Parmentier, M.; Moore, J.P.; Mackay, C.R. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med., 1997, 186(8), 1373-81.
24. Samson, M.; LaRosa, G.; Libert, F.; Paindavoine, P.; Detheux, M.; Vassart, G.; Parmentier, M. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J. Biol. Chem., 1997, 272(40), 24934-41.
25. Blanpain, C.; Doranz, B.J.; Bondue, A.; Govaerts, C.; De Leener, A.; Vassart, G.; Doms, R.W.; Proudfoot, A.; Parmentier, M. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem., 2003, 278(7), 5179-87.
26. Blanpain, C.; Doranz, B.J.; Vakili, J.; Rucker, J.; Govaerts, C.; Baik, S.S.; Lorthioir, O.; Migeotte, I.; Libert, F.; Baleux F.; Vassart G.; Doms R.W.; Parmentier M. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J. Biol. Chem., 1999, 274(49), 34719-27.
27. Blanpain, C.; Lee, B.; Vakili, J.; Doranz, B.J.; Govaerts, C.; Migeotte, I.; Sharron, M.; Dupriez, V.; Vassart, G.; Doms, R.W.; Parmentier, M. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J. Biol. Chem., 1999, 274(27), 18902-8.
28. Zhou, N.; Luo, Z.; Hall, J.W.; Luo, J.; Han, X.; Huang, Z. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur. J. Immunol., 2000, 30(1), 164-73.
29. Farzan, M.; Mirzabekov, T.; Kolchinsky, P.; Wyatt, R.; Cayabyab, M.; Gerard, N.P.; Gerard, C.; Sodroski, J.; Choe, H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell, 1999, 96(5), 667-76.
30. Rabut, G.E.; Konner, J.A.; Kajumo, F.; Moore, J.P.; Dragic, T. Alanine substitutions of polar and nonpolar residues in the aminoterminal domain of CCR5 differently impair entry of macrophageand dualtropic isolates of human immunodeficiency virus type 1. J. Virol., 1998, 72(4), 3464-8.
31. Dragic, T.; Trkola, A.; Lin, S.W.; Nagashima, K.A.; Kajumo, F.; Zhao, L.; Olson, W.C.; Wu, L.; Mackay, C.R.; Allaway, G.P.; Sakmar, T.P.; Moore, J.P.; Maddon, P.J. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol., 1998, 72(1), 279-85.
32. Huang, C.C.; Lam, S.N.; Acharya, P.; Tang, M.; Xiang, S.H.; Hussan, S.S.; Stanfield, R.L.; Robinson, J.; Sodroski, J.; Wilson, I.A.; Wyatt, R.; Bewley, C.A.; Kwong, P.D. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science, 2007, 317(5846), 1930-4.
33. Huang, C.C.; Tang, M.; Zhang, M.Y.; Majeed, S.; Montabana, E.; Stanfield, R.L.; Dimitrov, D.S.; Korber, B.; Sodroski, J.; Wilson, I.A.; Wyatt, R.; Kwong, P.D. Structure of a V3-containing HIV-1 gp120 core. Science, 2005, 310(5750), 1025-8.
34. Cormier, E.G.; Dragic, T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol., 2002, 76(17), 8953-7.
35. Farzan, M.; Choe, H.; Vaca, L.; Martin, K.; Sun, Y.; Desjardins, E.; Ruffing, N.; Wu, L.; Wyatt, R.; Gerard, N.; Gerard, C.; Sodroski, J. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol., 1998, 72(2), 1160-4.
36. Cormier, E.G.; Persuh, M.; Thompson, D.A.; Lin, S.W.; Sakmar, T.P.; Olson, W.C.; Dragic, T. Specific interaction of CCR5 aminoterminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(11), 5762-7.
37. Platt, E.J.; Kuhmann, S.E.; Rose, P.P.; Kabat, D. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. J. Virol., 2001, 75(24), 12266-78.
38. Laakso, M.M.; Lee, F.H.; Haggarty, B.; Agrawal, C.; Nolan, K.M.; Biscone, M.; Romano, J.; Jordan, A.P.; Leslie, G.J.; Meissner, E.G.; Su, L.; Hoxie, J.A.; Doms, R.W. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog., 2007, 3(8), e117.
39. Dean, M.; Carrington, M.; Winkler, C.; Huttley, G.A.; Smith, M.W.; Allikmets, R.; Goedert, J.J.; Buchbinder, S.P.; Vittinghoff, E.; Gomperts, E.; Donfield, S.; Vlahov, D.; Kaslow, R.; Saah, A.; Rinaldo, C.; Detels, R.; O’Brien, S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 1996, 273(5283), 1856-62.
40. Huang, Y.; Paxton, W.A.; Wolinsky, S.M.; Neumann, A.U.; Zhang, L.; He, T.; Kang, S.; Ceradini, D.; Jin, Z.; Yazdanbakhsh, K.; Kunstman, K.; Erickson, D.; Dragon, E.; Landau, N.R.; Phair, J.; Ho, D.D.; Koup, R.A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med., 1996, 2(11), 1240-3.
41. Liu, R.; Paxton, W.A.; Choe, S.; Ceradini, D.; Martin, S.R.; Horuk, R.; MacDonald, M.E.; Stuhlmann, H.; Koup, R.A.; Landau, N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 1996, 86(3), 367-77.
42. Samson, M.; Libert, F.; Doranz, B.J.; Rucker, J.; Liesnard, C.; Farber, C.M.; Saragosti, S.; Lapoumeroulie, C.; Cognaux, J.; Forceille, C.; Muyldermans, G.; Verhofstede, C.; Burtonboy, G.; Georges, M.; Imai, T.; Rana, S.; Yi, Y.; Smyth, R.J.; Collman, R.G.; Doms, R.W.; Vassart, G.; Parmentier, M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 1996, 382(6593), 722-5.
43. Michael, N.L.; Louie, L.G.; Rohrbaugh, A.L.; Schultz, K.A.; Dayhoff, D.E.; Wang, C.E.; Sheppard, H.W. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat. Med., 1997, 3(10), 1160-2.
44. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K.; Fujino, M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(10), 5698-703.
45. Nishikawa, M.; Takashima, K.; Nishi, T.; Furuta, R.A.; Kanzaki, N.; Yamamoto, Y.; Fujisawa, J. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother., 2005, 49(11), 4708-15.
46. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol., 2008, 73(3), 789-800.
47. Labrecque, J.; Metz, M.; Lau, G.; Darkes, M.C.; Wong, R.S.; Bogucki, D.; Carpenter, B.; Chen, G.; Li, T.; Nan, S.; Schols, D.; Bridger, G.J.; Fricker, S.P.; Skerlj, R.T. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay. Virology, 2011, 413(2), 231-43.
48. Baba, M.; Takashima, K.; Miyake, H.; Kanzaki, N.; Teshima, K.; Wang, X.; Shiraishi, M.; Iizawa, Y. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother., 2005, 49(11), 4584-91.
49. Imamura, S.; Ichikawa, T.; Nishikawa, Y.; Kanzaki, N.; Takashima, K.; Niwa, S.; Iizawa, Y.; Baba, M.; Sugihara, Y. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. J. Med. Chem., 2006, 49(9), 2784-93.
50. Tsamis, F.; Gavrilov, S.; Kajumo, F.; Seibert, C.; Kuhmann, S.; Ketas, T.; Trkola, A.; Palani, A.; Clader, J.W.; Tagat, J.R.; McCombie, S.; Baroudy, B.; Moore, J.P.; Sakmar, T.P.; Dragic, T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol., 2003, 77(9), 5201-8.
51. Tremblay, C.L.; Giguel, F.; Chou, T.C.; Dong, H.; Takashima, K.; Hirsch, M.S. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro. Antivir. Ther., 2005, 10(8), 967-8.
52. Carr, M.W.; Roth, S.J.; Luther, E.; Rose, S.S.; Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. U. S. A., 1994, 91(9), 3652-6.
53. Gathe, J.; Cade, J.; DeJesus, E. Week-24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with Emtricitabine/Tenofovir, in Treatment-naive HIV-1+ Adults with CCR5-tropic Virus, Abstract 106LB. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, 2013.
54. Marier, J.F.; Trinh, M.; Pheng, L.H.; Palleja, S.M.; Martin, D.E. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatmentexperienced, CCR5 antagonist-naive patients. Antimicrob. Agents Chemother., 2011, 55(6), 2768-74.
55. Lalezari, J.; Gathe, J.; Brinson, C.; Thompson, M.; Cohen, C.; Dejesus, E.; Galindez, J.; Ernst, J.A.; Martin, D.E.; Palleja S.M. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J. Acquir. Immune. Defic. Syndr., 2011, 57(2), 118-25.
56. Palani, A.; Shapiro, S.; Clader, J.W.; Greenlee, W.J.; Cox, K.; Strizki, J.; Endres, M.; Baroudy, B.M. Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1’-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4’-methyl-1,4’-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem., 2001, 44(21), 3339-42.
57. Strizki J.M.; Xu S.; Wagner N.E.; Wojcik L.; Liu J.; Hou Y.; Endres M.; Palani A.; Shapiro S.; Clader J.W.; Greenlee W.J.; Tagat J.R.; McCombie S.; Cox K.; Fawzi A.B.; Chou C.C.; Pugliese-Sivo C.; Davies L.; Moreno M.E.; Ho D.D.; Trkola A.; Stoddart C.A.; Moore J.P.; Reyes G.R.; Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(22), 12718-23.
58. Finlayson, K.; Witchel, H.J.; McCulloch, J.; Sharkey, J. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol., 2004, 500(1-3), 129-42.
59. Strizki, J.M.; Tremblay, C.; Xu, S.; Wojcik, L.; Wagner, N.; Gonsiorek, W.; Hipkin, R.W.; Chou, C.C.; Pugliese-Sivo, C.; Xiao, Y.; Tagat, J.R.; Cox, K.; Priestley, T.; Sorota, S.; Huang, W.; Hirsch, M.; Reyes, G.R.; Baroudy, B.M. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 2005, 49(12), 4911-9.
60. Tagat, J.R.; McCombie, S.W.; Nazareno, D.; Labroli, M.A.; Xiao, Y.; Steensma, R.W.; Strizki, J.M.; Baroudy, B.M.; Cox, K.; Lachowicz, J.; Varty, G.; Watkins, R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem., 2004, 47(10), 2405-8.
61. Caseiro, M.M.; Nelson, M.; Diaz, R.S.; Gathe, J.; de Andrade, N.J.L.; Slim, J.; Solano, A.; Netto, E.M.; Mak, C.; Shen, J.; Greaves, W.; Dunkle, L.M.; Vilchez, R.A.; Zeinecker, J. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. J. Infect., 2012, 65(4), 326-35.
62. Maeda, K.; Nakata, H.; Koh, Y.; Miyakawa, T.; Ogata, H.; Takaoka, Y.; Shibayama, S.; Sagawa, K.; Fukushima, D.; Moravek, J.; Koyanagi, Y.; Mitsuya, H. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol., 2004, 78(16), 8654-62.
63. Nakata, H.; Maeda, K.; Miyakawa, T.; Shibayama, S.; Matsuo, M.; Takaoka, Y.; Ito, M.; Koyanagi, Y.; Mitsuya, H. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. J. Virol., 2005, 79(4), 2087-96.
64. Crabb, C. GlaxoSmithKline ends aplaviroc trials. AIDS, 2006, 20(5), 641.
65. Dong, M.X.; Lu, L.; Li, H.; Wang, X.; Lu, H.; Jiang, S.; Dai, Q.Y. Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(9), 3284-6.
66. Hu, S.; Gu, Q.; Wang, Z.; Weng, Z.; Cai, Y.; Dong, X.; Hu, Y.; Liu, T.; Xie, X. Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. Eur. J. Med. Chem., 2014, 71, 259-66.
67. Kazmierski, W.M.; Danehower, S.; Duan, M.; Ferris, R.G.; Elitzin, V.; Minick, D.; Sharp, M.; Stewart, E.; Villeneuve, M. Biological and Structural Characterization of Rotamers of C-C Chemokine Receptor Type 5 (CCR5) Inhibitor GSK214096. ACS Med. Chem. Lett., 2014, 5(12), 1296-9.
68. Dorr, P.; Westby, M.; Dobbs, S.; Griffin P.; Irvine B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell C.; Napier C.; Webster R.; Armour D.; Price D.; Stammen B.; Wood A.; Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 2005, 49(11), 4721-32.
69. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem., 2005, 43, 239-71.
70. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B.; Bellos, N.; Saag, M.; Cooper, D.A.; Westby, M.; Tawadrous, M.; Sullivan, J.F.; Ridgway, C.; Dunne, M.W.; Felstead, S.; Mayer, H.; van der, R. E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med., 2008, 359(14), 1442-55.
71. Gulick, R.M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J.B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S.; Dunne, M.W.; van der, R. E.; Mayer, H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med., 2008, 359(14), 1429-41.
72. Vandekerckhove, L.; Verhofstede, C.; Vogelaers, D. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J. Antimicrob. Chemother., 2009, 63(6), 1087-96.
73. Cooper, D.A.; Heera, J.; Goodrich, J.; Tawadrous, M.; Saag, M.; Dejesus, E.; Clumeck, N.; Walmsley, S.; Ting, N.; Coakley, E.; Reeves, J.D.; Reyes-Teran, G.; Westby, M.; Van Der, R. E.; Ive, P.; Mohapi, L.; Mingrone, H.; Horban, A.; Hackman, F.; Sullivan, J.; Mayer, H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis., 2010, 201(6), 803-13.
74. Gorry, P.R.; Ellett, A.; Lewin, S.R. Maraviroc. In: Grayson, L.; Crowe, S.; McCarthy, J.; Mills, J.; Mouton, J.; Norrby SR, et al., editors. Kucers’ The Use of Antibiotics. 6th ed. London: Hodder & Stoughton; 2010.
75. Tan, Q.; Zhu, Y.; Li, J.; Chen Z.; Han G.W.; Kufareva I.; Li T.; Ma L.; Fenalti G.; Li J.; Zhang W.; Xie X.; Yang H.; Jiang H.; Cherezov V.; Liu H.; Stevens R.C.; Zhao Q.; Wu B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science, 2013, 341(6152), 1387-90.
76. Dragic, T.; Trkola, A.; Thompson, D.A.; Cormier, E.G.; Kajumo, F.A.; Maxwell, E.; Lin, S.W.; Ying, W.; Smith, S.O.; Sakmar, T.P.; Moore, J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(10), 5639-44.
77. Bai, Q.; Zhang, Y.; Li, X.; Chen, W.; Liu, H.; Yao, X. Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation. Phys. Chem. Chem. Phys., 2014, 16(44), 24332-8.
78. Tamamis, P.; Floudas, C.A. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One, 2014, 9(4), e95767.
79. Tilton, J.C.; Wilen, C.B.; Didigu, C.A.; Sinha, R.; Harrison, J.E.; Agrawal-Gamse, C.; Henning, E.A.; Bushman, F.D.; Martin, J.N.; Deeks, S.G.; Doms, R.W. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol., 2010, 84(20), 10863-76.
80. Kramer, V.G.; Schader, S.M.; Oliveira, M.; Colby-Germinario, S.P.; Donahue, D.A.; Singhroy, D.N.; Tressler, R.; Sloan, R.D.; Wainberg, M.A. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob. Agents Chemother., 2012, 56(8), 4154-60.
81. Kramer, V.G.; Hassounah, S.; Colby-Germinario, S.P.; Oliveira, M.; Lefebvre, E.; Mesplede, T.; Wainberg, M.A. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J. Antimicrob. Chemother., 2015, 70(3), 750-6.
82. Fouchier, R.A.; Groenink, M.; Kootstra, N.A.; Tersmette, M.; Huisman, H.G.; Miedema, F.; Schuitemaker, H. Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol., 1992, 66(5), 3183-7.
83. Isaka, Y.; Sato, A.; Miki, S.; Kawauchi, S.; Sakaida, H.; Hori, T.; Uchiyama, T.; Adachi, A.; Hayami, M.; Fujiwara, T.; Yoshie, O. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology, 1999, 264(1), 237-43.
84. De Jong, J.J.; De Ronde, A.; Keulen, W.; Tersmette, M.; Goudsmit, J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol., 1992, 66(11), 6777-80.
85. Cardozo, T.; Kimura, T.; Philpott, S.; Weiser, B.; Burger, H.; Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses, 2007, 23(3), 415-26.
86. Lengauer, T.; Sander, O.; Sierra, S.; Thielen A.; Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat. Biotechnol., 2007, 25(12), 1407-10.
87. Jensen, M.A.; Li, F.S.; van ‘t Wout, A.B.; Nickle, D.C.; Shriner, D.; He, H.X.; McLaughlin, S.; Shankarappa, R.; Margolick, J.B.; Mullins, J.I. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol., 2003, 77(24), 13376-88.
88. Cashin, K.; Gray, L.R.; Harvey, K.L.; Perez-Bercoff, D.; Lee, G.Q.; Sterjovski, J.; Roche, M.; Demarest, J.F.; Drummond, F.; Harrigan, P.R.; Churchill, M.J.; Gorry, P.R. Reliable genotypic tropism tests for the major HIV-1 subtypes. Sci. Rep., 2015, 5, 8543.
89. Cashin, K.; Gray, L.R.; Jakobsen, M.R.; Sterjovski, J.; Churchill, M.J.; Gorry, P.R. CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology, 2013, 10, 24.
90. De Jong, J.; Simon, F.; Van der, G.G.; Baan E.; Saragosti, S.; Brun-Vezinet, F.; Goudsmit, J. V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. AIDS Res. Hum. Retroviruses, 1996, 12(16), 1503-7.
91. de Jong, J.J.; Goudsmit, J.; Keulen, W.; Klaver, B.; Krone, W.; Tersmette, M.; de Ronde, A. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J. Virol., 1992, 66(2), 757-65.
92. Fouchier, R.A.; Brouwer, M.; Broersen, S.M.; Schuitemaker, H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J. Clin. Microbiol., 1995, 33(4), 906-11.
93. Milich, L.; Margolin, B.; Swanstrom, R. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J. Virol., 1993, 67(9), 5623-34.
94. Jansson, M.; Backstrom, E.; Scarlatti, G.; Bjorndal, A.; Matsuda, S.; Rossi, P.; Albert, J.; Wigzell, H. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses, 2001, 17(15), 1405-14.
95. Huang, W.; Toma, J.; Fransen, S.; Stawiski, E.; Reeves, J.D.; Whitcomb, J.M.; Parkin, N.; Petropoulos, C.J. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol., 2008, 82(11), 5584-93.
96. Boyd, M.T.; Simpson, G.R.; Cann, A.J.; Johnson, M.A.; Weiss, R.A. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J. Virol., 1993, 67(6), 3649-52.
97. Tsibris, A.M.; Korber, B.; Arnaout, R.; Russ, C.; Lo, C.C.; Leitner T.; Gaschen B.; Theiler J.; Paredes R.; Su Z.; Hughes, M.D.; Gulick, R.M.; Greaves W.; Coakley E.; Flexner C.; Nusbaum C.; Kuritzkes D.R. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One, 2009, 4(5), e5683.
98. Archer, J.; Braverman, M.S.; Taillon, B.E.; Desany, B.; James, I.; Harrigan, P.R.; Lewis, M.; Robertson, D.L. Detection of lowfrequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS, 2009, 23(10), 1209-18.
99. Bunnik, E.M.; Swenson, L.C.; Edo-Matas, D.; Huang, W.; Dong, W.; Frantzell, A.; Petropoulos, C.J.; Coakley, E.; Schuitemaker, H.; Harrigan, P.R.; van’t Wout, A.B. Detection of Inferred CCR5-and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing. PLoS Pathog., 2011, 7(6), e1002106.
100. Whitcomb, J.M.; Huang, W.; Fransen, S.; Limoli, K.; Toma, J.; Wrin, T.; Chappey, C.; Kiss, L.D.; Paxinos, E.E.; Petropoulos C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother., 2007, 51(2), 566-75.
101. Landovitz, R.J.; Angel, J.B.; Hoffmann, C.; Horst, H.; Opravil, M.; Long, J.; Greaves, W.; Fatkenheuer, G. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatmentnaive subjects with HIV-1 infection. J. Infect. Dis., 2008, 198(8), 1113-22.
102. Trinh, L.; Han, D.; Huang, W.; Wrin, T.; Larson, J.; Kiss, L.; Coakley, E.; Petropoulos, C.; Parkin, N.; Whitcomb, J.; Reeves, J. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antiviral Ther., 2008, 13(Suppl 3), A128.
103. Su, Z.; Gulick, R.M.; Krambrink, A.; Coakley, E.; Hughes, M.D.; Han, D.; Flexner, C.; Wilkin, T.J.; Skolnik, P.R.; Greaves, W.L.; Kuritzkes, D.R.; Reeves, J.D. Response to vicriviroc in treatmentexperienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J. Infect. Dis., 2009, 200(11), 1724-8.
104. Wilkin, T.J.; Goetz, M.B.; Leduc, R.; Skowron, G.; Su, Z.; Chan, E.S.; Heera, J.; Chapman, D.; Spritzler, J.; Reeves, J.D.; Gulick, R.M.; Coakley, E. Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity. Clin. Infect. Dis., 2011, 52(7), 925-8.
105. Svicher, V.; D’Arrigo, R.; Alteri, C.; Andreoni, M.; Angarano, G.; Antinori, A.; Antonelli, G.; Bagnarelli, P.; Baldanti, F.; Bertoli, A.; Borderi, M.; Boeri, E.; Bonn, I.; Bruzzone, B.; Callegaro, A.P.; Cammarota, R.; Canducci, F.; Ceccherini-Silberstein, F.; Clementi, M.; Monforte, A.D.; De Luca, A.; Di Biagio, A.; Di Gianbenedetto, S.; Di Perri, G.; Di Pietro, M.; Fabeni, L.; Fadda, G.; Galli, M.; Gennari, W.; Ghisetti, V.; Giacometti, A.; Gori, A.; Leoncini, F.; Maggiolo, F.; Maserati, R.; Mazzotta, F.; Micheli, V.; Meini, G.; Monno, L.; Mussini, C.; Nozza, S.; Paolucci, S.; Parisi, S.; Pecorari, M.; Pizzi, D.; Quirino, T.; Re, M.C.; Rizzardini, G.; Santangelo, R.; Soria, A.; Stazi, F.; Sterrantino, G.; Turriziani, O.; Viscoli, C.; Vullo, V.; Lazzarin, A.; Perno, C.F. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol., 2010, 33(3), 195-206.
106. McGovern, R.A.; Thielen, A.; Mo, T.; Dong, W.; Woods, C.K.; Chapman, D.; Lewis, M.; James, I.; Heera, J.; Valdez, H.; Harrigan, P.R. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS, 2010, 24(16), 2517-25.
107. Prosperi, M.C.; Bracciale, L.; Fabbiani, M.; Di Giambenedetto, S.; Razzolini, F.; Meini, G.; Colafigli, M.; Marzocchetti, A.; Cauda, R.; Zazzi, M.; De Luca, A. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology, 2010, 7, 56.
108. Sanchez, V.; Masia, M.; Robledano, C.; Padilla, S.; Ramos, J.M.; Gutierrez, F. Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J. Clin. Microbiol., 2010, 48(11), 4135-9.
109. Swenson, L.C.; Mo, T.; Dong, W.W.; Zhong, X.; Woods, C.K.; Jensen, M.A.; Thielen, A.; Chapman, D.; Lewis, M.; James, I.; Heera, J.; Valdez, H.; Harrigan, P.R. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis., 2011, 203(2), 237-45.
110. Saliou, A.; Delobel, P.; Dubois, M.; Nicot, F.; Raymond, S.; Calvez, V.; Masquelier, B.; Izopet, J. Concordance Between Two Phenotypic Assays and Ultra Deep Pyrosequencing for Determining HIV-1 Tropism. Antimicrob. Agents Chemother., 2011.
111. Swenson, L.C.; Mo, T.; Dong, W.W.; Zhong, X.; Woods, C.K.; Thielen, A.; Jensen, M.A.; Knapp, D.J.; Chapman, D.; Portsmouth, S.; Lewis, M.; James, I.; Heera, J.; Valdez, H.; Harrigan, P.R. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin. Infect. Dis., 2011, 53(7), 732-42.
112. Vandekerckhove, L.; Wensing, A.; Kaiser, R.; Brun-Vezinet, F.; Clotet, B.; De Luca, A.; Dressler, S.; Garcia, F.; Geretti, A.; Klimkait, T.; Korn, K.; Masquelier, B.; Perno, C.; Schapiro, J.; Soriano, V.; Sonnerborg, A.; Vandamme, A.M.; Verhofstede, C.; Walter, H.; Zazzi, M.; Boucher, C. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect. Dis., 2011.
113. Swenson, L.C.; Dong, W.W.; Mo, T.; Demarest, J.; Chapman, D.; Ellery, S.; Heera, J.; Valdez, H.; Poon, A.F.; Harrigan, P.R. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Clin. Infect. Dis., 2013, 56(11), 1659-66.
114. Sierra, S.; Dybowski, J.N.; Pironti, A.; Heider, D.; Guney, L.; Thielen, A.; Reuter, S.; Esser, S.; Fatkenheuer, G.; Lengauer, T.; Hoffmann, D.; Pfister, H.; Jensen, B.; Kaiser, R. Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc. PLoS One, 2015, 10(5), e0125502.
115. Svicher, V.; Alteri, C.; Montano, M.; Nori, A.; D’Arrigo, R.; Andreoni, M.; Angarano, G.; Antinori, A.; Antonelli, G.; Allice, T.; Bagnarelli, P.; Baldanti, F.; Bertoli, A.; Borderi, M.; Boeri, E.; Bon, I.; Bruzzone, B.; Barresi, R.; Calderisi, S.; Callegaro, A.P.; Capobianchi, M.R.; Gargiulo, F.; Castelli, F.; Cauda, R.; Ceccherini-Silberstein, F.; Clementi, M.; Chirianni, A.; Colafigli, M.; D’Arminio, M. A.; De Luca, A.; Di Biagio, A.; Di Nicuolo, G.; Di Perri, G.; Di Santo, F.; Fadda, G.; Galli, M.; Gennari, W.; Ghisetti, V.; Costantini, A.; Gori, A.; Gulminetti, R.; Leoncini, F.; Maffongelli, G.; Maggiolo, F.; Maserati, R.; Mazzotta, F.; Meini, G.; Micheli, V.; Monno, L.; Mussini, C.; Nozza, S.; Paolucci, S.; Palu, G.; Parisi, S.; Parruti, G.; Pignataro, A.R.; Quirino, T.; Re, M.C.; Rizzardini, G.; Sanguinetti, M.; Santangelo, R.; Scaggiante, R.; Sterrantino, G.; Turriziani, O.; Vatteroni, M.L.; Viscoli, C.; Vullo, V.; Zazzi, M.; Lazzarin, A.; Perno, C.F. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection, 2014, 42(1), 61-71.
116. Toma, J.; Frantzell, A.; Cook, J.; Hoh, R.; Martin, J.; Deeks, S.G.; Petropoulos, C.; Huang, W. Phenotypic Determination of HIV-1 Coreceptor Tropism Using Cell-associated DNA Derived from Blood Samples. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, USA: Am.Soc. Microbiol.; 2010. p. Abstract H-921.
117. Trkola, A.; Kuhmann, S.E.; Strizki, J.M.; Maxwell, E.; Ketas, T.; Morgan, T.; Pugach, P.; Xu, S.; Wojcik, L.; Tagat, J.; Palani, A.; Shapiro, S.; Clader, J.W.; McCombie, S.; Reyes, G.R.; Baroudy, B.M.; Moore, J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(1), 395-400.
118. Kuhmann, S.E.; Pugach, P.; Kunstman, K.J.; Taylor, J.; Stanfield, R.L.; Snyder, A.; Strizki, J.M.; Riley, J.; Baroudy, B.M.; Wilson, I.A.; Korber, B.T.; Wolinsky, S.M.; Moore, J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol., 2004, 78(6), 2790-807.
119. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol., 2007, 81(5), 2359-71.
120. Marozsan, A.J.; Kuhmann, S.E.; Morgan, T.; Herrera, C.; Rivera-Troche, E.; Xu, S.; Baroudy, B.M.; Strizki, J.; Moore, J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology, 2005, 338(1), 182-99.
121. Ogert, R.A.; Wojcik, L.; Buontempo, C.; Ba, L.; Buontempo, P.; Ralston, R.; Strizki, J.; Howe, J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology, 2008, 373(2), 387-99.
122. Asin-Milan, O.; Chamberland, A.; Wei, Y.; Haidara, A.; Sylla, M.; Tremblay, C.L. Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance. AIDS Res. Ther., 2013, 10(1), 15.
123. Yuan, Y.; Maeda, Y.; Terasawa, H.; Monde, K.; Harada, S.; Yusa, K. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology, 2011, 413(2), 293-9.
124. Baba, M.; Miyake, H.; Wang, X.; Okamoto, M.; Takashima, K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother., 2007, 51(2), 707-15.
125. Anastassopoulou, C.G.; Ketas, T.J.; Depetris, R.S.; Thomas, A.M.; Klasse, P.J.; Moore, J.P. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology, 2011, 413(1), 47-59.
126. Anastassopoulou, C.G.; Ketas, T.J.; Klasse, P.J.; Moore, J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(13), 5318-23.
127. Ogert, R.A.; Ba, L.; Hou, Y.; Buontempo, C.; Qiu, P.; Duca, J.; Murgolo, N.; Buontempo, P.; Ralston, R.; Howe, J.A. Structurefunction analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J. Virol., 2009, 83(23), 12151-63.
128. Pugach, P.; Marozsan, A.J.; Ketas, T.J.; Landes, E.L.; Moore, J.P.; Kuhmann, S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology, 2007, 361(1), 212-28.
129. Pugach, P.; Ray, N.; Klasse, P.J.; Ketas, T.J.; Michael, E.; Doms, R.W.; Lee, B.; Moore, J.P. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology, 2009, 387(2), 296-302.
130. Petropoulos, C.; Huang, W.; Toma, J.; Fransen, S.; Bonhoeffer, S.; Whitcomb, J. Resistance to HIV-1 Entry Inhibitors May Occur by Multiple Molecular Mechanisms. Antiviral Ther., 2004, 9(S25).
131. Tilton, J.C.; Amrine-Madsen, H.; Miamidian, J.L.; Kitrinos, K.M.; Pfaff, J.; Demarest, J.F.; Ray, N.; Jeffrey, J.L.; Labranche C.C.; Doms R.W. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retroviruses, 2010, 26(1), 13-24.
132. Roche, M.; Jakobsen, M.R.; Sterjovski, J.; Ellett, A.; Posta, F.; Lee, B.; Jubb, B.; Westby, M.; Lewin, S.R.; Ramsland, P.A.; Churchill, M.J.; Gorry, P.R. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism. J. Virol., 2011, 85, 4330-42.
133. Berro, R.; Klasse, P.J.; Lascano, D.; Flegler, A.; Nagashima, K.A.; Sanders, R.W.; Sakmar, T.P.; Hope, T.J.; Moore J.P. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol., 2011.
134. Berro, R.; Sanders, R.W.; Lu, M.; Klasse, P.J.; Moore, J.P. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog., 2009, 5(8), e1000548.
135. Latinovic, O.; Reitz, M.; Le, N.M.; Foulke, J.S.; Fatkenheuer, G.; Lehmann, C.; Redfield, R.R.; Heredia, A. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology, 2011, 411(1), 32-40.
136. Gulick, R.M.; Su, Z.; Flexner, C.; Hughes, M.D.; Skolnik, P.R.; Wilkin, T.J.; Gross, R.; Krambrink, A.; Coakley, E.; Greaves, W.L.; Zolopa, A.; Reichman, R.; Godfrey, C.; Hirsch, M.; Kuritzkes, D.R. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatmentexperienced patients: AIDS clinical trials group 5211. J. Infect. Dis., 2007, 196(2), 304-12.
137. Demarest, J.F.; Amrine-Madsen, H.; Irlbeck, D.M.; Kitrinos, K.M. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob. Agents Chemother., 2009, 53(3), 1116-23.
138. Kitrinos, K.M.; Amrine-Madsen, H.; Irlbeck, D.M.; Word, J.M.; Demarest, J.F. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob. Agents Chemother., 2009, 53(3), 1124-31.
139. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A.L.; James, I.T.; Jenkins, T.M.; Perros, M.; van der, R.E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol., 2006, 80(10), 4909-20.
140. Swenson, L.C.; Chui, C.K.; Brumme, C.J.; Chan, D.; Woods, C.K.; Mo, T.; Dong, W.; Chapman, D.; Lewis, M.; Demarest, J.F.; James, I.; Portsmouth, S.; Goodrich, J.; Heera, J.; Valdez, H.; Harrigan, P.R. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob. Agents Chemother., 2013, 57(12), 6122-30.
141. Westby, M.; van der, R. E. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir. Chem. Chemother., 2010, 20(5), 179-92.
142. Gathe, J. D.R.; Fatkenheuer, G.; Zeinecker, J.; Mak, C.; Vilchez, R.A.; Greaves, W.; Kumar, S.; Onyebuchi, C.; Dunkle, L.M. editor Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. 17th Conference on Retroviruses and Opportunistic Infections 2010 16-19 February; San Fransisco, CA, USA.
143. Suleiman J.; Zingman B.S.; Diaz R.S.; Madruga J.V.; DeJesus, E.; Slim, J.; Mak, C.; Lee, E.; McCarthy, M.C.; Dunkle, L.M.; Walmsley, S. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J. Infect. Dis., 2010, 201(4), 590-9.
144. McNicholas, P.; Wei, Y.; Whitcomb, J.; Greaves, W.; Black, T.A.; Tremblay, C.L.; Strizki, J.M. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J. Infect. Dis., 2010, 201(10), 1470-80.
145. McNicholas, P.M.; Mann, P.A.; Wojcik, L.; Phd, P.Q.; Lee, E.; McCarthy, M.; Shen, J.; Black, T.A.; Strizki, J.M. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J Acquir Immune. Defic. Syndr., 2011, 56(3), 222-9.
146. Tsibris, A.M.; Sagar, M.; Gulick, R.M.; Su, Z.; Hughes, M.; Greaves, W.; Subramanian, M.; Flexner, C.; Giguel, F.; Leopold, K.E.; Coakley, E.; Kuritzkes, D.R. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype Cinfected subject. J. Virol., 2008, 82(16), 8210-4.
147. Henrich, T.J.; Tsibris, A.M.; Lewine, N.R.; Konstantinidis, I.; Leopold, K.E.; Sagar, M.; Kuritzkes, D.R. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J. Acquir. Immune Defic. Syndr., 2010, 55(4), 420-7.
148. Ogert, R.A.; Hou, Y.; Ba, L.; Wojcik, L.; Qiu, P.; Murgolo, N.; Duca, J.; Dunkle, L.M.; Ralston, R.; Howe, J.A. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology, 2010, 400(1), 145-55.
149. Roche, M.; Salimi, H.; Duncan, R.; Wilkinson, B.L.; Chikere, K.; Moore, M.S.; Webb, N.E.; Zappi, H.; Sterjovski, J.; Flynn, J.K.; Ellett, A.; Gray, L.R.; Lee, B.; Jubb, B.; Westby, M.; Ramsland, P.A.; Lewin, S.R.; Payne, R.J.; Churchill, M.J.; Gorry, P.R. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology, 2013, 10, 43.
150. Putcharoen, O.; Lee, S.H.; Henrich, T.J.; Hu, Z.; Vanichanan, J.; Coakley, E.; Greaves, W.; Gulick, R.M.; Kuritzkes, D.R.; Tsibris, A.M. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J. Virol., 2012, 86(2), 1119-28.
151. Pfizer, I. Maraviroc Tablets NDA 22-128 Antiviral Drugs Advisory Committee (ADVAC) briefing document. 2007 24th April 2007. Report No.
152. Pfaff, J.M.; Wilen, C.B.; Harrison, J.E.; Demarest, J.F.; Lee, B.; Doms, R.W.; Tilton, J.C. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J. Virol., 2010, 84(13), 6505-14.
153. Henrich, T.J.; Lewine, N.R.; Lee, S.H.; Rao, S.S.; Berro, R.; Gulick, R.M.; Moore, J.P.; Tsibris, A.M.; Kuritzkes, D.R. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob. Agents Chemother., 2012, 56(4), 1931-5.
154. Isaacman-Beck, J.; Hermann, E.A.; Yi, Y.; Ratcliffe, S.J.; Mulenga, J.; Allen, S.; Hunter, E.; Derdeyn, C.A.; Collman, R.G. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J. Virol., 2009, 83(16), 8208-20.
155. Karlsson, I.; Antonsson, L.; Shi, Y.; Oberg, M.; Karlsson, A.; Albert J.; Olde B.; Owman C.; Jansson M.; Fenyo E.M. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J. Virol., 2004, 78(21), 11807-15.
156. Sterjovski, J.; Roche, M.; Churchill, M.J.; Ellett, A.; Farrugia, W.; Gray, L.R.; Cowley, D.; Poumbourios, P.; Lee, B.; Wesselingh, S.L.; Cunningham, A.L.; Ramsland, P.A.; Gorry, P.R. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology, 2010, 404(2), 269-78.
157. Harrison, J.E.; Lynch, J.B.; Sierra, L.J.; Blackburn, L.A.; Ray, N.; Collman, R.G.; Doms, R.W. Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J. Virol., 2008, 82(23), 11695-704.
158. Delobel, P.; Cazabat, M.; Saliou, A.; Loiseau, C.; Coassin, L.; Raymond, S.; Requena, M.; Marchou, B.; Massip, P.; Izopet, J. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence. J. Antimicrob. Chemother., 2013, 68(11), 2506-14.
159. Roche, M.; Jakobsen, M.R.; Ellett, A.; Salimiseyedabad, H.; Jubb, B.; Westby, M.; Lee, B.; Lewin, S.R.; Churchill, M.J.; Gorry, P.R. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology, 2011, 8, 89.
160. Johnston, S.H.; Lobritz, M.A.; Nguyen, S.; Lassen, K.; Delair, S.; Posta, F.; Bryson, Y.J.; Arts, E.J.; Chou, T.; Lee, B. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol., 2009, 83(21), 11016-26.
161. Ping, L.H.; Joseph, S.B.; Anderson, J.A.; Abrahams, M.R.; Salazar-Gonzalez, J.F.; Kincer, L.P.; Treurnicht, F.K.; Arney, L.; Ojeda, S.; Zhang, M.; Keys, J.; Potter, E.L.; Chu, H.; Moore, P.; Salazar, M.G.; Iyer, S.; Jabara, C.; Kirchherr, J.; Mapanje, C.; Ngandu, N.; Seoighe, C.; Hoffman, I.; Gao, F.; Tang, Y.; Labranche, C.; Lee, B.; Saville, A.; Vermeulen, M.; Fiscus, S.; Morris, L.; Karim, S.A.; Haynes, B.F.; Shaw, G.M.; Korber, B.T.; Hahn, B.H.; Cohen, M.S.; Montefiori, D.; Williamson, C.; Swanstrom, R. Study C.A.I.; the Center for H.I.V.A.V.I.C. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J. Virol., 2013, 87(13), 7218-33.
162. Parker, Z.F.; Iyer, S.S.; Wilen, C.B.; Parrish, N.F.; Chikere, K.C.; Lee, F.H.; Didigu, C.A.; Berro, R.; Klasse, P.J.; Lee, B.; Moore, J.P.; Shaw, G.M.; Hahn, B.H.; Doms, R.W. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol., 2013, 87(5), 2401-11.
163. Lassen, K.G.; Lobritz, M.A.; Bailey, J.R.; Johnston, S.; Nguyen, S.; Lee, B.; Chou, T.; Siliciano, R.F.; Markowitz, M.; Arts, E.J. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog., 2009, 5(4), e1000377.
164. Gray, L.; Sterjovski, J.; Churchill, M.; Ellery, P.; Nasr, N.; Lewin, S.R.; Crowe, S.M.; Wesselingh, S.L.; Cunningham, A.L.; Gorry, P.R. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology, 2005, 337(2), 384-98.
165. Anastassopoulou, C.G.; Marozsan, A.J.; Matet, A.; Snyder, A.D.; Arts, E.J.; Kuhmann, S.E.; Moore, J.P. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog., 2007, 3(6), e79.
166. Vaidya, N.K.; Rong, L.; Marconi, V.C.; Kuritzkes, D.R.; Deeks, S.G.; Perelson, A.S. Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput. Biol., 2010, 6(11), e1001012.
167. Lu, J.; Sista, P.; Giguel, F.; Greenberg, M.; Kuritzkes, D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol., 2004, 78(9), 4628-37.
168. Pugach, P.; Ketas, T.J.; Michael, E.; Moore, J.P. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology, 2008, 377(2), 401-7.
169. Alkhatib, G.; Locati, M.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology, 1997, 234(2), 340-8.
170. Yoshimura, K.; Harada, S.; Boonchawalit, S.; Kawanami, Y.; Matsushita, S. Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies. J. Gen. Virol., 2014, 95(Pt 8), 1816-26.
171. Richman, D.D.; Wrin, T.; Little, S.J.; Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(7), 4144-9.
172. Koning, F.A.; Koevoets, C.; van der, V. T.J.; Schuitemaker, H. Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir. Ther., 2005, 10(2), 231-7.
173. Etemad, B.; Fellows, A.; Kwambana, B.; Kamat, A.; Feng, Y.; Lee, S.; Sagar, M. Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J. Virol., 2009, 83(19), 9694-708.
174. Repits, J.; Oberg, M.; Esbjornsson, J.; Medstrand, P.; Karlsson, A.; Albert, J.; Fenyo, E.M.; Jansson, M. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol., 2005, 86(Pt 10), 2859-69.
175. Chatziandreou, N.; Arauz, A.B.; Freitas, I.; Nyein, P.H.; Fenton, G.; Mehta, S.H.; Kirk, G.D.; Sagar, M. Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers. AIDS Res. Hum. Retroviruses, 2012, 28(12), 1584-93.
176. Grossman, Z.; Meier-Schellersheim, M.; Paul, W.E.; Picker, L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med., 2006, 12(3), 289-95.
177. Okoye, A.; Meier-Schellersheim, M.; Brenchley, J.M.; Hagen, S.I.; Walker, J.M.; Rohankhedkar, M.; Lum, R.; Edgar, J.B.; Planer, S.L.; Legasse, A.; Sylwester, A.W.; Piatak, M.; Lifson, J.D.; Maino, V.C.; Sodora, D.L.; Douek, D.C.; Axthelm, M.K.; Grossman, Z.; Picker, L.J. Progressive CD4(+) central‚Aimemory T cell decline results in CD4(+) effector, Aimemory insufficiency and overt disease in chronic SIV infection. J. Exp. Med., 2007, 204(9), 2171-85.
178. Chomont, N.; El-Far, M.; Ancuta, P.; Trautmann, L.; Procopio, F.A.; Yassine-Diab, B.; Boucher, G.; Boulassel, M.R.; Ghattas, G.; Brenchley, J.M.; Schacker, T.W.; Hill, B.J.; Douek, D.C.; Routy, J.P.; Haddad, E.K.; Sekaly, R.P. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med., 2009, 15(8), 893-900.
179. Flynn, J.K.; Gorry, P.R. Stem memory T cells (TSCM)—their role in cancer and HIV immunotherapies. Clini. Transl. Immunol., 2014, 3, e20.
180. Flynn, J.K.; Paukovics, G.; Moore, M.S.; Ellett, A.; Gray, L.R.; Duncan, R.; Salimi, H.; Jubb, B.; Westby, M.; Purcell, D.F.; Lewin, S.R.; Lee, B.; Churchill, M.J.; Gorry, P.R.; Roche, M. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology, 2013, 442(1), 51-8.
181. Cashin, K.; Paukovics, G.; Jakobsen, M.R.; Ostergaard, L.; Churchill, M.J.; Gorry, P.R.; Flynn, J.K. Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4 + T-cell subsets, including stem cell memory T-cells. Retrovirology, 2014, 11(1), 97.
182. Gorry, P.R.; Ancuta, P. Coreceptors and HIV-1 pathogenesis. Curr. HIV/AIDS Rep., 2011, 8, 45-53.
183. Flynn, J.K.; Paukovics, G.; Cashin, K.; Borm, K.; Ellett, A.; Roche, M.; Jakobsen, M.R.; Churchill, M.J.; Gorry, P.R. Quantifying Susceptibility of CD4+ Stem Memory T-Cells to Infection by Laboratory Adapted and Clinical HIV-1 Strains. Viruses, 2014, 6(2), 709-26.
184. Liu, X.; Malins, L.R.; Roche, M.; Sterjovski, J.; Duncan, R.; Garcia, M.L.; Barnes, N.C.; Anderson, D.A.; Stone, M.J.; Gorry, P.R.; Payne, R.J. Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry. ACS Chem. Biol, 2014, 9(9), 2074-81.